US-based Medtronic has reportedly inked a deal with Ireland-based Covidien, a move that will lead to Medtronic to move its medical device manufacturing operations overseas.
Reports say Medtronic will acquire Covidien for $42.9 billion and move its executive base to Ireland. It’s part of a strategy by the US firm to reduce its tax burden, which will allow the company to allocate more funds for US investment, the company said.
The merger will also establish a greater competitor to current medical device behemoth Johnson & Johnson. The acquisition of Covidien will expand Medtronic’s medical device portfolio into weight-loss surgery and other services, according to reports.
The deal remains subject to regulatory approval.
In related news, the European Commission recently announced plans to investigate three member states, including Ireland, and their tax relationships with major companies including Starbucks and Apple.
Full content: Irish Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – China Edition – Year of the Dragon
Apr 16, 2024 by
CPI
Review Logic and Rules for Concentrations of Undertakings that Do Not Meet the Standard of Notification
Apr 16, 2024 by
CPI
China’s Review of Semiconductor Transactions
Apr 16, 2024 by
CPI
Key Challenges and Tips for Merger Control Filing in China for Listed Companies
Apr 16, 2024 by
CPI
Key Point Review: China SPC Antitrust Judgments in 2023
Apr 16, 2024 by
CPI